FXR-Gankyrin axis is involved in development of pediatric liver cancer-Reference-Cited by-同舟云学术

FXR-Gankyrin axis is involved in development of pediatric liver cancer

Published:2017-05-23 Issue:7 Volume:38 Page:738-747
ISSN:0143-3334
Container-title:Carcinogenesis
language:en
Short-container-title:

Author:

Valanejad Leila¹,Lewis Kyle¹,Wright Mary¹,Jiang Yanjun²,D’Souza Amber³,Karns Rebekah⁴,Sheridan Rachel⁵,Gupta Anita⁵,Bove Kevin⁵,Witte David⁵,Geller James³,Tiao Gregory¹,Nelson David L.⁶,Timchenko Lubov⁷,Timchenko Nikolai¹²

Affiliation:

1. Departments of Surgery,

2. Huffington Center on Aging, One Baylor Plaza, Houston, Texas, 77030, USA

3. Oncology,

4. Gastroenterology and

5. Pathology,

6. Department of Molecular and Human Genetics,

7. Neurology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA; Baylor College of Medicine,

Funder

NIH

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,General Medicine

Link

http://academic.oup.com/carcin/article-pdf/38/7/738/24346959/bgx050.pdf

Reference33 articles.

1. Molecular biology of liver cancer stem cells;Oishi;Liver Cancer,2014

2. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding;Carter;BMC Public Health,2012

3. Tumor suppressor and hepatocellular carcinoma;Martin;World J. Gastroenterol,2008

4. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches;Callegari;Cell Death Differ,2015

5. MicroRNAs as a novel class of diagnostic biomarkers in detection of hepatocellular carcinoma: a meta-analysis;Yin;Tumour Biol,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of Histone Deacetylase Activity Increases Cisplatin Efficacy to Eliminate Metastatic Cells in Pediatric Liver Cancers;Cancers;2024-06-22

2. Genetic Ablation of C/EBPα-p300 Pathway Blocks Development of Obese Pregnancy Associated Liver Disorders in Offspring;Cellular and Molecular Gastroenterology and Hepatology;2024

3. FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy;Biochemical Pharmacology;2023-06

4. p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act;Nutrients;2023-05-10

5. Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma;Cancers;2022-12-09